Circulars & Announcements - Ascentage Pharma

Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting

April 8, 2024

Voluntary Announcement Acquisition of Shares by Directors

April 3, 2024

Announcement of Annual Results for the Year Ended December 31, 2023

March 27, 2024

Dissemination of Corporate Communications

Mar 22, 2024

Notice of Board Meeting

Mar 15, 2024

Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February

Mar 6, 2024

Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Mar 6, 2024

Ascentage Pharma Received Clearance from U.S. FDA to Initiate Global Registrational Phase 3 Clinical Trial for Olverembatinib in Previously Treated Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Feb 14, 2024

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January

Feb 6, 2024

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

Feb 2, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December

Jan 7, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November

Dec 6, 2023

Olverembatinib Approved by NMPA for Treatment of CML-CP Patients who are Resistant and/or Intolerant to 1st and 2nd Generation TKI Treatment

Nov 17, 2023

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

Nov 16, 2023

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

Nov 14, 2023

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

Nov 13, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October

Nov 6, 2023

Ascentage Pharma to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology (ASH) Annual Meeting, two of which have been Selected for Oral Reports

Nov 3, 2023

Ascentage Pharma Presents Latest Data of APG-1252 (Pelcitoclax) in Combination with Osimertinib for NSCLC at 2023 ESMO

Oct 23, 2023

(pdf,53KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September

Oct 6, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August

Sep 5, 2023

Announcement of Unaudited Interim Results for the Six Months Ended June 30, 2023

Aug 21, 2023

(pdf,476KB)

Ascentage Pharma Received Clearance from U.S. FDA to Initiate Global Registrational Phase 3 Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Aug 7, 2023

Ascentage Pharma to Present Results from 2 Clinical Studies at 2023 ESMO Congress

Aug 3, 2023

(pdf,47KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June

Jul 5, 2023

Ascentage Pharma Announces CDE’s Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Jul 5, 2023

(pdf,48KB)

Change of Company Chinese Website

Jul 3, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May

Jun 6, 2023

Olverembatinib Recommended for a Breakthrough Therapy Designation
in China for the Treatment of SDH-Deficient GIST

May 31, 2023

Further Grant of Awards under the 2018 RSU Scheme and the 2021 RSU Scheme

May 29, 2023

(pdf,62KB)

Ascentage Pharma Presents Results from Four Studies at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2023

Poll Results of the Annual General Meeting Held on May 18, 2023

May 18, 2023

Further Grant of Awards under the 2022 RSU Scheme

May 8, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April

May 5, 2023

(pdf,72KB)

Ascentage Pharma Presents Results from 4 Studies
at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 27, 2023

Form of Proxy for the Annual General Meeting to be held on May 18, 2023

April 24, 2023

(pdf,72KB)

Proposed Re-election of Retiring Directors, Proposed Granting of General Mandates to Issue Shares and Repurchase Shares and Notice of Annual General Meeting

April 24, 2023

(pdf,197KB)

2021 Environmental, Social and Governance Report

April 24, 2023

Ascentage Pharma Presents Results from Three Studies at the 2023 American Association of Cancer Research Annual Meeting

April 18, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March

April 6, 2023

Announcement of Annual Results for the Year Ended December31, 2022

March 22, 2023

Ascentage Pharma has no business dealings with Silicon Valley Bank

March 12, 2023

Notice of Board Meeting

March 10, 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 Februray

March 6, 2023

(pdf,68KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January

February 6, 2023

Closing of Placing of Existing Shares and Top-up Subscription of New Shares under General Mandate

February 1, 2023

(pdf,147KB)

Next Day Disclosure Return

February 1, 2023

(pdf,92KB)

Placing of Existing Shares and Top-up Subscription of New Shares under General Mandate

January 18, 2023

(pdf,68KB)

Ascentage Pharma’s Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

January 18, 2023

(pdf,184KB)

Ascentage Pharma Delivers Oral Report on the Chinese and
US Studies of Olverembatinib (HQP1351) at 2022 ASH Annual Meeting

December 11, 2022

(pdf,68KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November

December 5, 2022

Ascentage Pharma’s Global Industrial Base Has
Obtained a Production License

November 27, 2022

(pdf,44KB)

Ascentage Pharma’s Global Industrial Base has
Obtained a Production License

November 27, 2022

Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report at the American Association for the Study of Liver Diseases Annual Meeting Showing Potential for Functionally Curing Chronic Hepatitis B

November 7, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October

November 4, 2022

Ascentage Pharma is to Present Five Studies of Olverembatinib, APG-2575, and APG-115 at the American Society of Hematology (ASH) Annual Meeting, Four of which have been Selected for Oral Presentations

November 3, 2022

Change of Company Email Address

November 1, 2022

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

October 31, 2022

Acquisition of Shares by the Chairman and Executive Director

October 30, 2022

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

October 28, 2022

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

October 26, 2022

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

October 25, 2022

Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

October 21, 2022

Ascentage Pharma to Announce Results from Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

October 20, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September

October 7, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August

September 6, 2022

Announcement of Unaudited Interim Results for the Six Months Ended June 30, 2022

August 26, 2022

(pdf,1.2MB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July

August 3, 2022

(pdf,66KB)

(1) Change of Principal Place of Business in HONG KONG and (2) Change of Address of HONG KONG BRANCH Share Registrar and Transfer Office

July 29, 2022

(pdf,431KB)

Study of Ascentage Pharma’s Olverembatinib Approved in Canada

July 22, 2022

Ascentage Pharma Announces that the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

July 19, 2022

Supplemental Announcement(1) Adoption of the 2022 RSU Scheme; and
(2) Initial Grant of Awards under the 2022 RSU Scheme

July 14, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June

July 7, 2022

Ascentage Pharma’s Novel Potent EED Inhibitor APG-5918 Obtained IND Clearance by the US FDA and will launch First-in-Human Study

Jun 29, 2022

(pdf,438KB)

(1) Adoption of the 2022 RSU Scheme; and (2) Initial Grant of Awards under the 2022 RSU Scheme

Jun 23, 2022

(pdf,472KB)

Ascentage Pharma Releases Encouraging Clinical Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

Jun 13, 2022

(pdf,442KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May

Jun 7, 2022

(pdf,467KB)

2021 Environmental, Social and Governance Report

May 31, 2022

(pdf,5MB)

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

May 27, 2022

(pdf,467KB)

Ascentage Pharma to Present Latest Clinical Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at 2022 European Hematology Association Hybrid Congress

May 23, 2022

(pdf,440KB)

(1) Poll Results of the Annual General Meeting Held on MAY 19, 2022; (2) Resignation of Non-executive Directors; (3) Change in Composition of the Remuneration Committee; and (4) Amendments to Memorandum and Articles of Association

May 19, 2022

(pdf,448KB)

The Companies Act(As Amended) Company Limited by Shares Second Amended and Restated Memorandum and Articles of Association of Ascentage Pharma Group international

May 19, 2022

(pdf,688KB)

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib’s Therapeutic Potential in Treating COVID-19 Published
in EMBO Molecular Medicine

May 18, 2022

(pdf,444KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April

May 6, 2022

Resubmission of Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March

April 28, 2022

Ascentage to Present Data from Seven Clinical Studies at ASCO 2022

April 28, 2022

(pdf,440KB)

Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

April 14, 2022

Notice of Annual General Meeting

April 13, 2022

Proposed Re-election of Retiring Directors, Proposed Granting of General Mandates to Issue Shares and Repurchase Shares, Proposed Amendments to the Memorandum and Articles of Association and Notice of Annual General Meeting

April 13, 2022

Form of Proxy for the Annual General Meeting to be Held on MAY 19, 2022

April 13, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March

April 7, 2022

Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma

March 22, 2022

Proposed Amendments to the Amended and Restated Memorandum and Articles of Association

March 21, 2022

ANNOUNCEMENT OF ANNUAL RESULTS
FOR THE YEAR ENDED DECEMBER 31, 2021

March 21, 2022

(pdf,893KB)

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Bcl-2 Selective Inhibitor Lisaftoclax (APG-2575) for the Treatment of R/R CLL/SLL

March 15, 2022

Notice of Board Meeting

March 9, 2022

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at American Association for Cancer Research (AACR) Annual Meeting 2022

March 9, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February

March 3, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January

February 9, 2022

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December

January 6, 2022

Ascentage Pharma Presents Results of Six Studies of Three Novel Drug Candidates under Development (Olverembatinib, APG-2575, and APG-1252) at the 63rd American Society of Hematology (ASH)
Annual Meeting

December 14, 2021

(pdf,466KB)

Ascentage Pharma Announces CDE’s Approval for the Phase II Pivotal Study in
China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

December 13, 2021

(pdf,438KB)

Ascentage Pharma and Clover Enter into Clinical Collaboration to Jointly Develop IAP Antagonist, APG-1387, in Combination with Recombinant Human TRIAL-Trimer Fusion Protein, SCB-313,for the Treatment of Peritoneal Carcinomatosis

December 9, 2021

Next Day Disclosure Return

December 8, 2021

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November

December 3, 2021

(pdf,66KB)

Appointment of Chief Financial Officer

November 29, 2021

(pdf,455KB)

Ascentage Pharma Announces Approval by NMPA for China’s First Approved Third-Generation
BCR-ABL TKI HQP1351 (Olverembatinib)

November 25, 2021

(pdf,455KB)

Ascentage Pharma’s core drug candidate HQP1351 (Olverembatinib) Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia

November 22, 2021

(pdf,449KB)

On-market Repurchase of Shares

November 11, 2021

Next Day Disclosure Return

November 11, 2021

On-market Repurchase of Shares

November 10, 2021

Next Day Disclosure Return

November 10, 2021

(pdf,87KB)

On-market Repurchase of Shares

November 9, 2021

Next Day Disclosure Return

November 9, 2021

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in the Treatment of Metastatic ER+/HER2- Breast Cancer

November 8, 2021

(pdf,475KB)

On-market Repurchase of Shares

November 8, 2021

Next Day Disclosure Return

November 8, 2021

On-market Repurchase of Shares

November 5, 2021

(pdf,475KB)

Next Day Disclosure Return

November 5, 2021

(pdf,32KB)

Abstracts on six studies of Ascentage Pharma’s three drug candidates under development (Olverembatinib, APG-2575, and APG-1252) have been
selected for oral presentation and poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

November 5, 2021

(pdf,475KB)

Next Day Disclosure Return

November 4, 2021

(pdf,87KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October

November 4, 2021

(pdf,61KB)

On-market Repurchase of Shares

November 4, 2021

Resignation of Chief Financial Officer

November 1, 2021

Completion of the Issuance of Unlisted Warrants under Specific Mandate

October 12, 2021

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September

October 7, 2021

(pdf,63KB)

Ascentage Pharma’s MDM2-p53 Inhibitor APG-115 Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

September 23, 2021

(pdf,441KB)

Poll Results of the Extraordinary General Meeting Held on September 20,2021

September 20, 2021

(pdf,438KB)

(1) Disclosable Transactions — Subscription of Commercial Paper and Structured Financial Products and (2) Supplemental Announcement in relation to the 2021 Interim Report

September 10, 2021

(pdf,114KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August

September 6, 2021

(pdf,63KB)

Form of Proxy for the Extraordinary General Meeting to be Held on September 20, 2021

August 31, 2021

(pdf,589KB)

Notice Of Extraordinary General Meeting

August 31, 2021

(pdf,82KB)

Circular (1) Connected Transaction — Proposed Grant of RSUs to Connected Selected Persons;(2) Proposed Grant of RSU Specific Mandate to Issue Shares under the 2021 RSU scheme; (3) Proposed Grant of Warrant Specific Mandate to Issue Unlisted Warrants and Warrant Shares and (4) Notice of Extraordinary General Meeting

August 31, 2021

(pdf,1MB)

Retirement of Chief Operating Officer

August 30, 2021

(pdf,61KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July(Revised)

August 29, 2021

Announcement of Unaudited Interim Results for the Six Months Ended JUNE 30, 2021

August 24, 2021

(pdf,437KB)

Notice of Board Meeting

August 12, 2021

(pdf,57KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July

August 5, 2021

(pdf,984KB)

Delay in Despatch of Circular in relation to (1) Proposed Issuance of Unlisted Warrants under Specific Mandate; and (2) Connected Trsansactions — Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors and Chief Commercial Officer

July 30, 2021

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

July 28, 2021

(pdf,440KB)

Connected Transaction Cancellation of Proposed Grant of Awards and Proposed Re-grant of Awards under the 2021 RSU Scheme to independent non-executive Directors

July 24, 2021

(pdf,446KB)

Next Day Disclosure Return

July 23, 2021

(pdf,32KB)

Ascentage Pharma’s MDM2-p53 Inhibitor, APG-115 (Alrizomadlin), Received an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma

July 21, 2021

(pdf,446KB)

Ascentage Pharma Establishes Cooperation with the US National Cancer Institute to advance the Clinical Development of Ascentage Pharma’s Bcl-2/Bcl-xL inhibitor APG-1252

July 20, 2021

(pdf,441KB)

Inside Information – Entry Into of the HQP1351 Collaboration and License agreement and the APG2575 Combination Therapy Strategic Collaboration and Clinical Trial Agreement; Issuance of New Shares under General Mandate; and Proposed Issuance of Unlisted Warrants under Specific Mandate

July 14, 2021

(pdf,159KB)

Connected Transaction Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors Appointment of Independent Financial Adviser

July 14, 2021

(pdf,446KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June

July 6, 2021

(pdf,278KB)

Next Day Disclosure Return

June 29, 2021

(pdf,169KB)

2020 Environmental, Social and Governance Report

June 29, 2021

(pdf,5MB)

CLARIFICATION ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS

June 25, 2021